Hanmi Pharmaceutical's Hyperlipidemia Treatment Enters Mexico
[Asia Economy Reporter Cho Hyun-ui] Hanmi Pharmaceutical's independently developed combination drug for dyslipidemia treatment, 'Rosuzet,' is entering the Mexican market.
Hanmi Pharmaceutical announced on the 1st that its partner MSD has received marketing approval from the Mexican regulatory authority for Rosuzet (Mexican product name: NAXZALLA) in three dosages: 10/5mg, 10/10mg, and 10/20mg.
Rosuzet is a combination drug that contains two active ingredients for treating dyslipidemia, rosuvastatin and ezetimibe. It effectively lowers blood LDL-C by dual inhibition of cholesterol synthesis and absorption in the liver and intestines. It is a blockbuster specialty drug with the highest outpatient prescription sales among combination drugs developed by domestic pharmaceutical companies.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Woo Jong-su, CEO of Hanmi Pharmaceutical, said, “Rosuzet is a product that holds a solid leading position in the domestic dyslipidemia combination drug market,” and added, “We will do our best to expand the export countries of Rosuzet and other competitive products that embody Hanmi’s excellent formulation technology.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
